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The aim of this study is to further investigate the immune response of the inactivated split-virion vaccine for infants.
We tested the immunogenicity and safety of the inactivated split-virion vaccine in infants, aged 6–35 months, for a
randomized, observer-masked, age-stratified clinical study. We randomly divided subjects into three groups: 7.5 μg,
15 μg of hemagglutinin antigen dosage groups and seasonal influenza vaccine for children dosage group in a 2
dose regimen. A serologic analysis was performed at baseline and on day 21 and 42. 312 infants received a single
dose injection of vaccine and 265 (84.94%) infants received two doses injection of vaccine. Adverse reactions were
mostly mild or moderate. Among the subjects who received 7.5 μg and 15 μg of vaccine for a single dose injection,
the rate of hemagglutinin inhibition titer of 1:40 or greater were 52.48% (95% confidence interval (CI) 42.83 ~ 61.95)
and 61.11% (95% CI 50.78 ~ 70.53), respectively. Among the subjects receiving 7.5 μg and 15 μg of vaccine for two
doses injection, the rate of hemagglutinin inhibition (HI) titer of 1:40 or greater were 90.10% (95% CI 82.73 ~ 94.53)
and 94.44% (95% CI 87.64 ~ 97.60), respectively. These data suggests that 15 μg or 7.5 μg dose of hemagglutinin
antigen of the inactivated split-virion vaccine was safe and two doses of injection could induce a sufficient
protective immune response in infants.
Trial registration: Clinical trials registration: NCT01494740.
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In April, 2009, a previously undescribed influenza A
(H1N1) virus was isolated from people in Mexico and the
United States, and then spreaded rapidly to many countries
around the world. On June 11, 2009, a new influenza pan-
demic was officially declared by World Health Organization
(WHO) (Dawood et al. 2009; World Health Organization
2009a). As of 18 July 2010, more than 214 countries around
the world and overseas territories or communities have
reported laboratory confirmed cases of pandemic influenza
H1N1 2009, including over 18366 deaths (World Health
Organization 2010a). During the outbreak, the children are
mostly likely to be among the infected. Inconsistent with
the traditional seasonal influenza, the 2009 influenza A
(H1N1) virus is more likely to infect young people, rather* Correspondence: chenze2005@hotmail.com
†Equal contributors
1Shanghai Institute of Biological Products, Shanghai 200052, China
Full list of author information is available at the end of the article
© 2014 Wang et al.; licensee Springer. This is a
Attribution License (http://creativecommons.or
in any medium, provided the original work is pthan older people (Dawood et al. 2009; Echevarría-Zuno
et al. 2009; Fraser et al. 2009; Domínguez-Cherit et al. 2009;
Kumar et al. 2009; Donaldson et al. 2009). Across the re-
ports of the 2009 influenza A (H1N1) virus infection cases,
about 60% were young people less than 18 years of age, and
the susceptibility of young children, which was further evi-
denced by the high hospitalization rates of those younger
than 4 years (Centers for Disease Control and Prevention
(CDC) 2009; Dawood et al. 2009).
The effectiveness of influenza vaccination in children
to reduce the virus infection in the pandemic has been
well demonstrated (Neuzil KM et al. 2001; Ruben 2004).
Many countries and vaccine manufacturers have started
to develop influenza vaccines against the 2009 influenza
A (H1N1) virus, and evaluated the effect of vaccines in
clinical trials. In Australia, the clinical trials have proved
that one dose of the monovalent, split-virion vaccine
without adjuvant was safe for people aged 18–64 years,
and the seroconversion rates were 74.20% with 15 μg ofn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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determining the 2009 influenza A (H1N1) vaccine was
safe and could induce strong immune responses in healthy
adults, the immune effect of vaccine in people of a small
age group was studied further. In China, clinical trials
have evaluated the safety and immunogenicity of the 2009
influenza A (H1N1) vaccine in people aged 3–60 years
and our results have been published on the WHO website
(Liang XF et al. 2010; Ze & Yang 2010). In addition, we
also reported the long-term immunogenicity of the 2009
influenza A (H1N1) vaccine in the people aged 18–60
years (Yang et al. 2012). Subsequently, some papers
reported the immune response in people under the age of
3 with 15 μg and 30 μg of hemagglutinin antigen dosage,
which proved that the 2009 influenza A (H1N1) vaccine
was safe and could induce enough immune response.
Our main purpose is to assess the safety and immuno-
genicity of the monovalent, unadjuvanted, split-virion
2009 influenza A (H1N1) vaccine in infants. In our study,
infants under the age of 3 were divided into three age
groups: 6–12 months, 13–24 months and 25–35 months
in order to study the immune effects of the vaccine in
infants. We described the immune responses of infants
aged 6–35 months after being given 2 doses of injection
with 7.5 μg and 15 μg of hemagglutinin antigen.
Methods
Study design
From December 2009 to January 2010, we carried out the
double-blind, single-center clinical trial in Luxi County,
Xiangxi Autonomous Prefecture, Hunan Province (China).
The purpose of this study was to evaluate the safety and
immunogenicity of the split-virion 2009 influenza A
(H1N1) vaccine in healthy infants aged 6–35 months and
these infants were divided into three groups: aged 6–12
months, 13–24 months and 25–35 months. All subjects
received two doses of 7.5 μg, 15 μg hemagglutinin antigen
or seasonal influenza vaccine with intervals three weeks
apart. All of the pilot programs, clinical manuals and other
materials used in this study were consistent with the
Declaration of Helsinki and the quality control require-
ments for clinical trials, and were approved by the Ethics
Committee of Hunan Province.
Vaccines
The monovalent, inactivated, split-virion 2009 influenza A
(H1N1) vaccine was developed by the Shanghai Institute
of Biological Products, and the seed virus was prepared
from the reassortant vaccine virus A/California/7/2009
NYMC X-179A, as recommended by the WHO (World
Health Organization 2009b; World Health Organization
2010b). The vaccine was prepared in embryonated chicken
eggs according to the standard techniques used in the
production of seasonal influenza vaccine. In brief, thevirus was amplified in chicken embryos, then harvested
and inactivated with formaldehyde. The viral cultures were
then concentrated and purified for use as the final vac-
cine. The experimental vaccines were split-virus prod-
ucts containing 7.5 μg of hemagglutinin antigen per
dose (0.25 ml) and 15 μg of hemagglutinin antigen per
dose (0.5 ml). The virus strains of the seasonal vaccine
for children (SI) (A/Brisbane/59/2007 H1N1-like; A/
Brisbane/10/2007 H3N2-like; and B/Brisbane/60/2008-
like strains) were chosen according to the WHO recom-
mendations for use in the 2009–10 influenza season
(northern hemisphere winter). Vaccines contained 7.5 μg
of hemagglutinin per strain per dose.
The vaccine was approved for clinical use by the Chinese
National Institute for the Control of Pharmaceutical and
Biological Products (China) and in full compliance with
the Pharmacopoeia standards.
Participants
All subjects must be strictly in line with the standard of
ages 6–35 months. Infants with confirmed or suspected
2009 influenza A (H1N1) infection or those who had
received other influenza products within 6 months were
excluded from the study and the eligible infants did not
have history of allergy or contraindications to the vac-
cine. All the infants were full-term babies and weighed
more than 2500 grams. All subjects participated volun-
tarily in the clinical trials and their written informed
consent was obtained from the parent or guardian of the
infants. The blind testing was designed by a third party
at Central South University, who was not involved in
other elements of the clinical trials.
Eligible infants were stratified in three groups by age: aged
6–12 months with 52 subjects, 13–24 months with 130
subjects and 25–35 months with 130 subjects. After stratifi-
cation, infants were randomized to receive the 7.5 μg, 15 μg
of hemagglutinin antigen or seasonal influenza vaccine.
Injections were given intramuscularly in the deltoid
muscle and 21 days after vaccination, the subjects were
inoculated with the same dose of vaccine. Because the
injection volume differed in the study doses, we have
taken measures to avoid affecting the results of clinical
trial. Serum samples were collected before or on days
21, 42 after vaccination.
Safety
Induced local and systemic adverse events were recorded
by the infant’s parent or guardian using a 7-day diary card,
and other adverse events were recorded using a 21-day
diary card. All local adverse events were considered related
to the H1N1 vaccine. The systemic adverse events include:
fever, allergic reactions, headache, fatigue, vomiting, diar-
rhea, coughing, crying, breastfeeding or eating disorders.
The local adverse events include: (injection point) pain,
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verse events tests and decisions were referred to the stan-
dards of the Division of Microbiology and Infectious
Diseases, US National Institutes of Health (NIAID Division
of Microbiology and Infectious Diseases 2007a; NIAID
Division of Microbiology and Infectious Diseases 2007b).
Immunogenicity
The antibody titers against the vaccine strain were de-
termined by HI assays of the anti-homologous strain
of X-179A, performed in accordance with established
measures using turkey erythrocytes. In brief, sera were
firstly treated with receptor destroy enzyme at 36°C
for 16 hours. The titers of HI antibody that were below
the detection limit (i.e., <1:10) were recorded at a value
of 1:5, and titers above 1:10240 were recorded at a
value of 1:10240. The seroconversion rate represented
a post-vaccination titer ≥1:40 in subjects with a pre-
vaccination titer of <1:10 or a ≥4-fold titer increase in
subjects with a pre-vaccination titer of ≥1:10. All serum
samples were assayed in a blinded manner, in duplicate,Table 1 Participant disposition
Dosage Age Dose Subjects
Male, No
15 μg 6 ~ 12 m 1 20 10
2 16 9
13 ~ 24 m 1 50 25
2 39 20
25 ~ 35 m 1 50 26
2 42 22
Total 1 120 61
2 97 51
7.5 μg 6 ~ 12 m 1 20 10
2 19 9
13 ~ 24 m 1 50 25
2 41 21
25 ~ 35 m 1 50 25
2 44 22
Total 1 120 60
2 104 52
SI 6 ~ 12 m 1 12 6
2 10 5
13 ~ 24 m 1 30 15
2 28 14
25 ~ 35 m 1 30 15
2 26 14
Total 1 72 36
2 64 33and were checked in parallel by the Chinese National
Institute for the Control of Pharmaceutical and Biological
Products.
Statistical analysis
For immunogenicity assessments, the seroconversion
rate represented either a post-vaccination titer ≥1:40 (in
accordance with the requirements for seasonal influenza
vaccines by the European Committee for Proprietary
Medicinal Products) in subjects with a pre-vaccination
titer of <1:10 or a ≥4-fold titer increase in subjects with
a pre-vaccination titer of ≥1:10. A seroprotection rate
>70% was considered to provide protection. In addition,
the geometric mean increase (GMI) was the ratio of the
titer after vaccination to the titer before vaccination. All
the serum data analysed in this research was from the
subjects who received blood collections four times
(European Agency for the Evaluation of Medicinal Prod-
ucts (EMEA) 1997).
Hypothesis testing was conducted using two-sided
tests, with an alpha value of 0.05 considered to indicateSex Age, Mean
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performed using the SPSS software package (version 11.5).
Results
Study participants
A total of 312 subjects between 6 and 35 months of age
participated in the clinical trial. Among them, 52 sub-
jects were 6–12 months of age, 130 subjects were 13–24
months of age and 130 subjects were 25–35 months of
age. Firstly, the 312 subjects were vaccinated and 312
serum samples were collected initially. Secondly, 265
subjects were vaccinated and 265 serum samples were
collected. 25 subjects were gradually withdrawn from
the clinical trial and 22 subjects refused to provide the
serum. After 2 doses of injection, 252 serum samples
were collected and 13 subjects refused to provide the
serum. The specific vaccination data including gender,
months of age are shown in Table 1. Of the 312 enrolled
subjects, 252 subjects (80.77%) completed the entire
study, providing three serum samples.
Safety of the vaccine
The overall adverse reaction rates are shown in Figure 1.
After one dose of injection, the 7.5 μg group had a mild
adverse reaction rate of 10.83% and the moderate
adverse reaction rate of 6.67%. The 15 μg group had a
mild adverse reaction rate of 10.83% and the moderate
adverse reaction rate of 8.33%. The SI group had a mild
adverse reaction rate of 6.25% and the moderate adverse
reaction rate of 6.25%. In all groups, no serious adverse
reactions were detected. Fever was the most frequently
reported adverse effect. After one dose of injection, the
fever reaction rate in the 7.5 μg, 15 μg and SI group
were 11.67%, 13.33% and 9.72%, respectively. After two
doses of injection, the fever reaction rate in the 7.5 μg,Figure 1 Reactogenicity in all subjects: the total adverse reaction rate15 μg and SI group were 14.42%, 15.46% and 12.50%,
respectively. In addition to fever, eating disorders,
vomiting, diarrhea, coughing, crying and other adverse
reactions have occurred in the study dose group. Except
for vomiting, other adverse reactions have occurred in
the SI.
Immune response
Before vaccination, the proportion of subjects showing
HI ≥1:40 was 29.55% in the 6–12 months of age group
with the highest observed, 18.27% in the 13–24 months
of age group and 19.23% in the 25–35 months of age
group (Table 2, Table 3).
Immune responses were induced in all subjects after
vaccination. After one dose of injection, the rates of
seroconversion and seroprotection in the 7.5 μg group
were 39.60% and 52.48%, and the HI Geometric mean
titer (GMT) growth multiple was 37.86. The rates of
seroconversion and seroprotection in the 15 μg group
were 48.89% and 61.11%, and the HI GMT was 51.57.
After two doses of injection, the rates of seroconversion
and seroprotection in the vaccine groups were all in-
creased. The rates of seroconversion and seroprotection
in the 7.5 μg group were 85.15% and 90.10%, and the HI
GMT was 163.34. The rates of seroconversion and sero-
protection in the 15 μg group were 92.22% and 94.44%,
and the HI GMT was 221.11.
After one dose of injection, in the 7.5 μg group, the rates
of seroconversion and seroprotection were 36.84% and
63.16% in the 6–12 months of age group, 34.15% and 39.02%
in the 13–24 months of age group, 46.34% and 60.98%
in the 25–35 months of age group. Except the rate of
seroprotection in the 13–24 months of age group was
lower than that of the other two groups, the rates of
seroconversion and seroprotection in the 6–12 monthss within 7 days after each vaccine dose.
Table 2 Proportion of participants with seroprotection and seroconversion in the various groups
Dosage Age Baseline 21 days after injection 42 days after injection
SP rate (95% CI) SC rate (95% CI) SP rate (95% CI) SC rate (95% CI) SP rate (95% CI)
15 μg 6-12 m 13.33 26.67 33.33 93.33 93.33
(3.73 ~ 37.88)b (10.90 ~ 51.95) (15.17 ~ 58.28) (70.18 ~ 98.81)a (70.18 ~ 98.81)a
13-24 m 32.43 51.35 67.57 94.59 94.59
(19.63 ~ 48.53)b (35.89 ~ 66.55)a (51.47 ~ 80.37)ab (82.29 ~ 98.50)a (82.29 ~ 98.50)a
25-35 m 21.05 55.26 65.79 89.47 94.74
(11.07 ~ 36.34) (39.70 ~ 69.85)a (49.89 ~ 78.79)a (75.86 ~ 95.83)a (82.72 ~ 98.55)a
Total 24.44 48.89 61.11 92.22 94.44
(16.73 ~ 34.24) (38.82 ~ 59.05)a (50.78 ~ 70.53)a (84.80 ~ 96.18)a (87.64 ~ 97.60)a
7.5 μg 6-12 m 47.37 36.84 63.16 89.47 100.00
(27.33 ~ 68.29) (19.15 ~ 58.96) (41.04 ~ 80.85)a (68.60 ~ 97.06)a (83.18 ~ 100.00)a
13-24 m 9.76 34.15 39.02 80.49 82.93
(3.86 ~ 22.55)a (21.56 ~ 49.45) (25.65 ~ 54.27) (65.99 ~ 89.77)a (68.74 ~ 91.48)a
25-35 m 19.51 46.34 60.98 87.80 92.68
(10.23 ~ 34.01) (32.05 ~ 61.25)a (45.73 ~ 74.35)a (74.45 ~ 94.67)a (80.57 ~ 97.48)a
Total 20.79 39.60 52.48 85.15 90.10
(14.02 ~ 29.70) (30.61 ~ 49.35)a (42.83 ~ 61.95)a (76.93 ~ 90.79)a (82.73 ~ 94.53)a
SI 6-12 m 20.00 0.00 20.00 10.00 30.00
(5.67 ~ 50.98) (0.00 ~ 27.75) (5.67 ~ 50.98) (1.79 ~ 40.41) (10.78 ~ 60.32)
13-24 m 11.54 3.85 15.38 3.85 15.38
(4.00 ~ 28.98) (0.68 ~ 18.90) (6.15 ~ 33.53) (0.68 ~ 18.90) (6.15 ~ 33.53)
25-35 m 16.00 0.00 16.00 12.00 28.00
(6.40 ~ 34.65) (0.00 ~ 13.32) (6.40 ~ 34.65) (4.17 ~ 29.96) (14.28 ~ 47.58)
Total 14.75 1.64 16.39 8.20 22.95
(7.96 ~ 25.72) (0.29 ~ 8.72) (9.15 ~ 27.61) (3.55 ~ 17.80) (14.19 ~ 34.91)
aP < 0.05 compared with the SI group.
bP < 0.05 compared with the 7.5 dose group.
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difference. And in the 15 μg group, the rates of serocon-
version and seroprotection were 26.67% and 33.33% in
the 6–12 months of age group, 51.35% and 67.57% in the
13–24 months of age group, 55.26% and 65.79% in the
25–35 months of age group. Except for the rate of
seroprotection in the 6–12 months of age group that was
lower than that of the other two groups, the rates of sero-
conversion and seroprotection in the 13–24 months and
25–35 months of age groups all had no significant differ-
ence. The difference in the rates of seroprotection in the
different months of age groups may be related to the
difference in the baseline antibody titers.
After two doses of injection, in the 7.5 μg group, the
rates of seroconversion and seroprotection were 89.47%
and 100.00% in the 6–12 months of age group, 80.49% and
89.93% in the 13–24 months of age group, 87.80% and
92.68% in the 25–35 months of age group. The rates of
seroconversion and seroprotection in the three months
of age groups all had no significant difference. And inthe 15 μg group, the rates of seroconversion and sero-
protection were 93.33% and 93.33% in the 6–12 months
of age group, 94.59% and 94.59% in the 13–24 months of
age group, 89.47% and 94.74% in the 25–35 months of age
group. Similarly, the rates of seroconversion and seropro-
tection in the three months of age groups all had no
significant difference.
In the SI group, the proportion of HI ≥1:40 post-
vaccination had increased slightly compared to the values
of pre-vaccination (14.75%). The protection rate was
16.39% after one dose of injection and 22.95% after two
doses of injection. Similarly, the GMT of the HI antibody
titers was 8.34 after one dose of injection and 13.44 after
two doses of injection.
In summary, in the subjects administered with two
doses of 7.5 μg vaccine, the rates of seroconversion and
seroprotection met the requirements specified by the
EMEA (The European Agency for the Evaluation of Me-
dicinal Products). The results showed that the vaccine
could provide protection against the 2009 H1N1 virus.
Table 3 Geometric mean titer (GMT) and the geometric mean increase (GMI) in the various groups











15 μg 6-12 m 7.58 16.63 2.19 145.88 19.25
(4.34 ~ 13.24)b (8.11 ~ 34.07)b (1.30 ~ 3.69)b (80.39 ~ 264.73)a (12.32 ~ 30.08)a
13-24 m 13.75 63.90 4.65 255.56 18.59
(9.03 ~ 20.94) (37.46 ~ 108.97)a (3.22 ~ 6.70)a (170.61 ~ 382.91)a (11.59 ~ 29.81)a
25-35 m 10.37 65.45 6.31 226.26 21.82
(6.50 ~ 16.55) (40.06 ~ 106.95)a (4.14 ~ 9.62)a (151.81 ~ 337.21)a (13.80 ~ 34.48)a
Total 11.05 51.57 4.67 221.11 20.00
(8.42 ~ 14.51) (37.07 ~ 71.76)a (3.63 ~ 6.00)a (172.15 ~ 283.99)a (15.19 ~ 26.34)a
7.5 μg 6-12 m 22.32 66.67 2.99 276.57 12.39
(9.97 ~ 49.91) (28.58 ~ 155.49)a (1.85 ~ 4.81)a (166.88 ~ 458.35)a (7.16 ~ 21.44)a
13-24 m 7.63 25.34 3.32 116.04 15.21
(5.67 ~ 10.27) (15.15 ~ 42.39)a (2.24 ~ 4.93)a (75.11 ~ 179.31)a (10.57 ~ 21.89)a
25-35 m 10.70 43.53 4.07 180.09 16.83
(6.87 ~ 16.65) (28.89 ~ 65.58)a (2.85 ~ 5.80)a (124.11 ~ 261.33)a (11.20 ~ 25.30)a
Total 10.71 37.86 3.54 163.34 15.25
(8.22 ~ 13.95) (27.83 ~ 51.50)a (2.82 ~ 4.44)a (127.06 ~ 209.94)a (12.03 ~ 19.33)a
SI 6-12 m 9.33 8.71 0.93 14.14 1.52
(3.62 ~ 24.08) (3.77 ~ 20.09) (0.80 ~ 1.09) (4.70 ~ 42.60) (0.69 ~ 3.31)
13-24 m 7.87 8.52 1.08 12.05 1.53
(4.68 ~ 13.22) (5.51 ~ 13.18) (0.83 ~ 1.41) (7.67 ~ 18.94) (1.10 ~ 2.13)
25-35 m 8.71 8.01 0.92 14.74 1.69
(5.30 ~ 14.29) (5.19 ~ 12.37) (0.81 ~ 1.04) (8.57 ~ 25.35) (1.19 ~ 2.41)
Total 8.43 8.34 0.99 13.44 1.59
(6.14 ~ 11.58) (6.35 ~ 10.95) (0.87 ~ 1.12) (9.74 ~ 18.54) (1.28 ~ 1.99)
aP < 0.05 compared with the SI group.
bP < 0.05 compared with the 7.5 dose group.
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It is well-known that influenza can cause infection in
different age stratification and spread fast. However, chil-
dren and the elderly are more susceptible to influenza
virus and the rates of infection are highest among chil-
dren resulting in serious illness and death. In infants
below 2 years old, the hospitalization rates are much
higher than the older infants and children, and the risk
of receiving influenza-related complications are also
higher than that of other age groups (Fiore et al. 2008).
So, the infants are the primary targets of the influenza
vaccine to control influenza pandemic.
Some papers have reported the safety and immunogen-
icity of the 2009 influenza A (H1N1) vaccine in people
aged >3 years old. The results showed that a single 7.5 μg
of this monovalent 2009 influenza A (H1N1) vaccine can
induce enough antibody responses (Greenberg et al. 2009;
Liang XF et al. 2010). However, Walter EB indicated that,
due to the immature immune system or not infected bythe influenza virus, the vaccine induced significant lower
antibody responses in infants aged <1 year old (Walter EB
et al. 2010). Thus, it is necessary to study the immunogen-
icity of the 2009 influenza A (H1N1) vaccine in infants.
Previous studies have explored the immune effect of
vaccine in infants aged <3 years old. In the UK, after two
7.5 μg doses of injection with the whole virus influenza
vaccine in infants aged <12 years old, the proportion of
subjects showing HI ≥1:32 was 78.20% (Waddington CS
et al. 2010). Among them, the proportion of subjects
showing HI ≥1:32 was 65.70% in 6 months to 3 years of
age. In Australia, a single 15 μg of the inactivated split-
virion H1N1 vaccine caused a significant increase of the
specific antibody in 86.78% of the infants aged 6 months
to 9 years (Nolan et al. 2010). In South Korea, after one
7.5 μg dose of injection with the inactivated split-virion
H1N1 vaccine in infants aged 6 months to 3 years, the
proportion of subjects showing HI ≥1:40 was 55.90%
(Chi-Eun et al. 2010).
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monovalent 2009 influenza A (H1N1) vaccine can induce
stronger antibody responses in infants (aged 6 months to
3 years). After immunization, the rates of seroprotection
and seroconversion were 90.10% and 85.15% respectively
and the GMI was 15.25. The above results met the standard
of vaccine immunogenicity required by European Union
Committee for Medicinal Products.
Similar to many results reported previously, a higher
than expected proportion of infants exhibited baseline
antibody titers greater than 1:40 (Greenberg et al. 2009;
Nolan et al. 2010). While we excluded infants with con-
firmed H1N1 infection, these results illustrated the high
number of recessive infection in infants. Our study was
carried out in 8 months after the outbreak of the H1N1
virus, which increased the possibility of the people
subjected with recessive infected with influenza virus. In
addition, the results showed that the proportion of the
people recessive infected with influenza virus was differ-
ent in different areas of China.
In the SI group, the proportion of HI antibody against
2009 H1N1 virus ≥ 40 was 16.39% after one dose of injection
and 22.95% after two doses of injection. The seasonal vaccine
did not provide protection against 2009 H1N1 virus in
infants. These results were consistent with those reported
in other papers that little cross-reactive antibody against
the 2009 H1N1 virus after seasonal vaccination (Centers
for Disease Control and Prevention (CDC) 2009).
In our study, the proportion of infants aged 6 months
to 3 years showing baseline antibody titers greater than
1:40 was 20.63%. After one dose of 7.5 μg vaccine, the
rates of antibody titers greater than 1:40 in three age
groups were 63.16%, 39.02% and 60.98%, respectively.
After one dose of 15 μg vaccine, the rates of antibody
titers greater than 1:40 in the three age groups were
33.33%, 67.57% and 65.79%, respectively. These results
were higher than those reported by the South Korea and
lower than those reported by the Australia, which may
be influenced by the baseline antibody titers (Chi-Eun
et al. 2010; Nolan et al. 2010). The baseline antibody
titer of different months of age groups had significant
differences. After one dose of injection, the rates of
seroprotection in the three months of age groups had
significant differences. After two doses of injection, the
rates of seroconversion and seroprotection in the three
months of age groups had no significant difference. The
above results showed that only two doses of injection of
the monovalent 2009 influenza A (H1N1) vaccine could
induce enough antibody responses in infants and also
avoided the difference of the rates of seroprotection
caused by the baseline antibody titer. In addition, the
results also verified the recommendation of the Centers
for Disease Control and Prevention, which the Advisory
Committee on Immunization Practices suggested thatinfants and children aged 6 months to 9 years should
receive 2 doses of H1N1 influenza vaccine.
Our study showed that 7.5 μg dose of the monovalent
2009 influenza A (H1N1) vaccine was well tolerated and
immunogenic, which could provide protection for in-
fants and reduce the spread of the virus in the influenza
pandemic.
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